benfluorex sold brand name mediator anorectic hypolipidemic agent structurally related fenfluramine substituted amphetamine may improve glycemic control decrease insulin resistance people poorly controlled market thought caused patented manufactured french pharmaceutical company servier however servier suspected marketed benfluorex odds drugs medical march french court fined servier finding guilty deception december european medicines agency recommended withdrawal medicines containing benfluorex european union risks particularly risk heart valve disease fenfluraminelike cardiovascular side effects greater thus frachon et al showed higher rate unexplained valvular heart disease people taking weill et al looked million people diabetes demonstrating higher hospitalization rate benfluorex takers valvular heart france medication marketed servier adjuvant antidiabetic name mediator drug market thought caused drug also used spain portugal cyprus march french court fined servier finding guilty deception manslaughter mediator linked deaths people former executive jeanphilippe seta sentenced suspended jail sentence four years french medicines agency accused failing act quickly enough warnings drug fined pharmaceutical group acquitted charges fraud fenfluramine related drug withdrawn market reports heart valve pulmonary hypertension development cardiac fibrosis side effect mediated metabolite norfenfluramine receptors heart leading characteristic pattern heart failure following proliferation cardiac fibroblasts tricuspid valve fenfluramine benfluorex form norfenfluramine metabolite side effect led withdrawal fenfluramine anorectic drug worldwide later withdrawal benfluorex europe stimulants phenylethanolamine httpsenwikipediaorgwikibenfluorex